Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Wave Life Sciences Ltd. (Nasdaq: WVE) is set to host a live webcast and conference call on May 3, 2023, at 8:30 a.m. ET to discuss its first quarter 2023 financial results and provide business updates. Analysts can participate in the Q&A session via an audio conferencing link. The archived version of the webcast will later be available on the company's website. Wave Life Sciences is focused on developing genetic medicines for severe diseases using its proprietary PRISM platform, which aims to create high-quality stereopure oligonucleotides. This initiative reflects the company's commitment to improving patient outcomes for genetically defined diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced the publication of preclinical data revealing their small interfering RNA (siRNA) designs demonstrate superior potency and durability for gene silencing compared to comparator formats. In a study, a Wave siRNA maintained approximately 80% silencing of HSD17B13 transcripts in transgenic mice for three months, contrasting with 60% silencing observed in a comparator siRNA which returned close to baseline by three months. The study highlighted a significant 10-fold increase in Ago2 loading with Wave’s siRNA due to innovative PN backbone modifications. This advancement reaffirms Wave's potential in RNAi therapeutics and its collaboration with GSK, reflecting a commitment to developing cutting-edge genetic medicines.
Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on April 3, 2023, at 2:10 p.m. ET. The event aims to discuss the company's commitment to developing innovative genetic medicines for serious diseases.
A live webcast of the presentation will be accessible on the Investor Relations page of their corporate website, with an archived replay available for a limited period post-event.
Wave Life Sciences (WVE) reported its financial results for Q4 and the full year 2022, highlighting a net loss of $43.7 million in Q4 and $161.8 million for the year, attributed mainly to increased clinical program expenses. The company achieved clinical validation of its PRISM platform and advanced WVE-006, its first RNA editing candidate, into clinical development for AATD. A strategic collaboration with GSK may yield up to $3.3 billion in milestone payments. Wave has a solid cash position with $88.5 million available, expected to sustain operations into 2025. Key upcoming milestones include new clinical data in 2023.